ICYMI: Congress Calls For Increased Oversight and Transparency of 340B Program

The House Energy & Commerce Subcommittee on Oversight and Investigations held a hearing last Tuesday to examine the Health Resources and Services Administration’s (HRSA) oversight of the 340B drug pricing program.